B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients

Figures & data

Figure 1. Outline of vaccination and sample collection schedule.

Table 1. Demographic and clinical characteristics of participants.

	Patients on dialysis	Controls
n	22	20
Female, n (%)	8 (36%)	11 (55%)
Age, median (IQR)	71.5 (60.75–80.25)	61 (55.25–65)
Ethnicity (Jewish) (%)	12 (54%)	16 (80%)
Participants receiving hemodialysis	22 (100%)	—
Underlying disease of dialysis Patients:
Diabetes, n (%)	10 (45.5)	—
Hypertension, n (%)	4 (18)	—
Glumerolo nephritis, n (%)	1 (4.5)	—
Other renal disease, n (%)	7 (32)	—
Immunosuppressive treatment	—	N.A.

Table 2. Number of vaccinations and specimen contributions of study participants. *At T1 eleven and nine samples were collected from PoD and controls for T cell evaluation respectively and at T4 six samples were collected from PoD. PoD=Patients on dialysis.

	Patients on dialysis	Controls
Received 3 doses n (%)	22 (100%)	20 (100%)
Received 4 doses n (%)	7 (32%)	10 (50%)
Contributed blood at T1	16*	11*
Contributed blood at T2	15	12
Contributed blood at T3	14	8
Contributed blood at T4	7*	10

Figure 2. Anti SARS-CoV-2-Spike IgG levels in serum of dialysis patients (red) and controls (blue) at T1 (1–2 months pre 3^rd dose), T2 (1–3 months post 3^rd dose), T3 (4–5 months post 3^rd dose) and T4 (2–4 months post 4^th dose). Numbers of participants included are indicated in the graph.

Figure 3. Frequencies of SARS-CoV-2 Spike specific memory B cells in dialysis patients (red) and controls (blue) at T1 (1–2 months pre 3^rd dose), T2 (1–3 months post 3^rd dose), T3 (4–5 months post 3^rd dose) and T4 (2–4 months post 4^th dose). A: Spike specific memory B cell (CD19+CD27+) expressed as a proportion of the total B cell population (CD19+) and B: Spike specific memory B cells expressing IgG presented as a proportion of total spike specific CD19+CD27+ cells (B). Number of participants included are indicated in the graph.

Figure 4. Frequencies of SARS-CoV-2 Spike specific T cells (CD3+CD4+CD154+) in dialysis patients (red) and controls (blue) presented as a proportion of CD3+CD4+ cells at T1 (1–2 months pre 3^rd dose), T2 (1–3 months post 3^rd dose), T3 (4–5 months post 3^rd dose) and T4 (2–4 months post 4^th dose). Number of participants included in the statistical analysis are indicated in the graph.

Figure 5. Frequencies of SARS-CoV-2 Spike specific T cells from the CD3+CD4+ (A) and CD3+CD8+ (B) T cell population expressing both IFN∎ and TNF√ in dialysis patients (red) and controls (blue) at T1 (1–2 months pre 3^rd dose), T2 (1–3 months post 3^rd dose), T3 (4–5 months post 3^rd dose) and T4 (2–4 months post 4^th dose). Number of participants included in the statistical analysis are indicated in the graph.

Data availability statement

The data that support the findings of this study are available from the corresponding author, N.T, upon reasonable request.